Compare Agilent Technologies Inc (A) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs MobilEye Global Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while MobilEye Global Inc trades at $8.88 (market cap $7.44B). The key difference: Agilent Technologies Inc is far larger — about 5.6× MobilEye Global Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| A | MBLY | |
|---|---|---|
Market Cap | $42.00B | $7.44B |
Sector | Health | Technology |
52-Week High | $157.20 | $15.54 |
52-Week Low | $110.24 | $6.56 |
Enterprise Value | $43.55B | $6.00B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Mobileye Global (MBLY) trades at $8.73, up 3.68% with a bullish technical outlook despite negative profitability metrics. The stock shows strong analyst support with 61.5% buy ratings and an $11.40 consensus target, representing 30.6% upside potential. Recent Q2 2026 earnings beat expectations with $0.19 EPS versus $0.06 estimate, while the company faces leadership transition as founder Amnon Shashua steps down after 27 years.
The investment case balances strong revenue growth and market positioning in autonomous driving technology against significant profitability challenges and leadership uncertainty. While the company benefits from expanding partnerships like the Stellantis ADAS deal, investors must weigh the -201.49% net margin and negative cash flow projections for 2026 against the substantial upside potential indicated by analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
